Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis.

about

Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis.

Item

http://www.wikidata.org/entity/Q38411334

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis.

@en

type

Item

label

Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis.

@en

prefLabel

Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis.

@en

P1476

Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis.

@en

P2093

Atsushi Ogata

http://www.w3.org/2001/XMLSchema#string

Takayoshi Morita

http://www.w3.org/2001/XMLSchema#string

Toshio Tanaka

http://www.w3.org/2001/XMLSchema#string

Yuji Yoshida

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies

The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic dr

The pathogenesis of rheumatoid arthritis

A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients.

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.

Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis.

P304

283-295

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4155/TDE.14.118

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25853305

http://www.w3.org/2001/XMLSchema#string